Reducing Elevated Plasma LDL Cholesterol: The Central Role of the LDL Receptor

High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm

(2014) S Tuteja et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the Future

(2014) R Hajhosseiny et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Current Approach to Statin Intolerance

(2014) R Tompkins et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Measurement of Low-Density Lipoprotein Cholesterol in Assessment and Management of Cardiovascular Disease Risk

(2014) I Jialal et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

An Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias

(2014) F H Rached et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenomics, Lipid Disorders, and Treatment Options

(2014) S E Gryn et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Heart Disease and Stroke Statistics—2014 Update

(2013) Alan S. Go et al.   CIRCULATION

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

(2012) Frederick Raal et al.   CIRCULATION

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Beyond LDL Cholesterol, a New Role for PCSK9

(2010) Omar N. Akram et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Once-a-Week Rosuvastatin (2.5 to 20 mg) in Patients With a Previous Statin Intolerance

(2008) Janelle F. Ruisinger et al.   AMERICAN JOURNAL OF CARDIOLOGY

PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide

(2008) LiXin Shan et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS